iSpecimen Amends S-1 for Public Offering, Maintains Emerging Growth Status
Ticker: ISPC · Form: S-1/A · Filed: May 23, 2025 · CIK: 1558569
Sentiment: neutral
Topics: S-1/A, IPO, Emerging Growth Company, Biotech Services, SEC Filing, Public Offering, Regulatory Compliance
Related Tickers: ISPC
TL;DR
**ISPC is still pushing for an IPO, but its 'emerging growth' status screams high risk, high reward.**
AI Summary
iSpecimen Inc. filed an S-1/A on May 23, 2025, as an amendment to its initial S-1 registration statement (Registration No. 333-286958). The filing indicates the company is a non-accelerated filer, a smaller reporting company, and an emerging growth company, suggesting it has not yet achieved significant revenue or market capitalization. The amendment primarily updates the registration statement for a proposed sale to the public, offering securities on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933. Key business changes are not detailed in this specific amendment, which focuses on regulatory compliance and offering mechanics rather than financial performance. The filing does not provide specific dollar amounts for revenue or net income, nor does it outline key business changes or strategic outlook. Risks are implicitly related to being an emerging growth company and the uncertainties of a public offering.
Why It Matters
This S-1/A filing is crucial for investors as it signals iSpecimen Inc.'s continued intent to go public, potentially offering new investment opportunities in the commercial physical & biological research sector. For employees, a successful public offering could lead to increased liquidity for equity compensation and enhanced company visibility. Customers might see increased investment in services and technology, while the broader market gains another publicly traded entity in the biotech services space, intensifying competition. The company's status as an emerging growth company suggests higher growth potential but also higher risk compared to established competitors.
Risk Assessment
Risk Level: high — iSpecimen Inc. is explicitly designated as a 'smaller reporting company' and an 'emerging growth company' in the S-1/A filing. This status indicates a lack of substantial operating history, limited financial resources, and potentially volatile stock performance, as defined by Rule 12b-2 of the Exchange Act. The absence of specific financial figures in this amendment further contributes to the high-risk assessment.
Analyst Insight
Investors should approach iSpecimen Inc. with caution, recognizing the inherent risks of an emerging growth company. Conduct thorough due diligence on the company's financials, business model, and competitive landscape once the full S-1 becomes effective. Consider a small, speculative position only if the company's long-term growth prospects align with a high-risk tolerance.
Key Numbers
- 333-286958 — Registration No. (Original S-1 registration statement number for iSpecimen Inc.)
- 8731 — SIC Code (Standard Industrial Classification for Commercial Physical & Biological Research)
- 27-0480143 — IRS Employer Identification Number (iSpecimen Inc.'s EIN)
- 781-301-6700 — Business Phone (Contact number for iSpecimen Inc.'s principal executive offices)
Key Players & Entities
- iSpecimen Inc. (company) — Registrant for S-1/A filing
- Robert Bradley Lim (person) — Agent for service for iSpecimen Inc.
- Yuying Liang (person) — Agent for service for iSpecimen Inc.
- Ross D. Carmel, Esq. (person) — Counsel from Sichenzia Ross Ference Carmel LLP
- Joseph M. Lucosky, Esq. (person) — Counsel from Lucosky Brookman LLP
- Barry P. Biggar, Esq. (person) — Counsel from Lucosky Brookman LLP
- Steven A. Lipstein, Esq. (person) — Counsel from Sichenzia Ross Ference Carmel LLP
- Benjamin E. Sklar, Esq. (person) — Counsel from Sichenzia Ross Ference Carmel LLP
- Lucosky Brookman LLP (company) — Legal counsel for iSpecimen Inc.
- Sichenzia Ross Ference Carmel LLP (company) — Legal counsel for iSpecimen Inc.
FAQ
What is the purpose of iSpecimen Inc.'s S-1/A filing?
The S-1/A filing by iSpecimen Inc. on May 23, 2025, is an amendment to its initial S-1 registration statement (Registration No. 333-286958), primarily to update the document for a proposed public sale of securities on a delayed or continuous basis under Rule 415.
What is iSpecimen Inc.'s status as an SEC filer?
iSpecimen Inc. is designated as a non-accelerated filer, a smaller reporting company, and an emerging growth company, as indicated in its S-1/A filing on May 23, 2025.
Who are the legal counsels listed in iSpecimen Inc.'s S-1/A filing?
The legal counsels listed in iSpecimen Inc.'s S-1/A filing include Ross D. Carmel, Esq. and Steven A. Lipstein, Esq. from Sichenzia Ross Ference Carmel LLP, and Joseph M. Lucosky, Esq. and Barry P. Biggar, Esq. and Benjamin E. Sklar, Esq. from Lucosky Brookman LLP.
What is the business address for iSpecimen Inc.?
The business address for iSpecimen Inc. is 8 Cabot Road, Suite 1800, Woburn, MA 01801, with a business phone number of (781) 301-6700, as stated in the S-1/A filing.
When was iSpecimen Inc.'s S-1/A amendment filed?
iSpecimen Inc.'s Amendment No. 1 to Form S-1 (S-1/A) was filed with the Securities and Exchange Commission on May 23, 2025.
What is the Standard Industrial Classification (SIC) code for iSpecimen Inc.?
iSpecimen Inc.'s Primary Standard Industrial Classification Code Number is 8731, which corresponds to Services-Commercial Physical & Biological Research.
Does the S-1/A filing provide financial performance details for iSpecimen Inc.?
No, this specific S-1/A filing primarily focuses on regulatory updates and the mechanics of the proposed public offering, and it does not contain specific dollar amounts for revenue, net income, or other detailed financial performance metrics for iSpecimen Inc.
What are the implications of iSpecimen Inc. being an 'emerging growth company'?
Being an 'emerging growth company' means iSpecimen Inc. qualifies for certain scaled-back disclosure requirements and exemptions from various regulatory provisions, which can reduce compliance costs but also implies a less extensive operating history and potentially higher investment risk.
Who is the agent for service for iSpecimen Inc.?
The agents for service for iSpecimen Inc. are Robert Bradley Lim and Yuying Liang, both located at 8 Cabot Road, Suite 1800, Woburn, MA 01801, with a phone number of (781) 301-6700.
What is the approximate date of commencement of proposed sale to public for iSpecimen Inc.?
The approximate date of commencement of proposed sale to public for iSpecimen Inc. is stated as 'As soon as practicable after this Registration Statement is declared effective' in the S-1/A filing.
Industry Context
iSpecimen Inc. operates within the commercial physical and biological research sector (SIC Code 8731). This industry is characterized by its role in supporting scientific advancement through the provision of biological specimens and related services. The competitive landscape involves companies that can reliably source, process, and deliver high-quality biological materials for research and development purposes.
Regulatory Implications
As a non-accelerated filer, smaller reporting company, and emerging growth company, iSpecimen Inc. is subject to specific SEC regulations. The S-1/A filing indicates compliance with the Securities Act of 1933 for its public offering. The company's status allows for scaled disclosure requirements, potentially reducing the immediate burden of extensive financial reporting.
What Investors Should Do
- Review the full S-1/A filing for detailed business descriptions and risk factors.
- Monitor future filings for updated financial performance and offering details.
Key Dates
- 2025-05-23: Filing of S-1/A Amendment No. 1 — This amendment updates the initial registration statement, indicating the company is moving forward with a public offering of securities on a delayed or continuous basis.
Glossary
- S-1/A
- An amendment to a Form S-1 registration statement filed with the SEC. It's used to update or correct information in the original filing before or during a public offering. (This is the primary document type filed by iSpecimen Inc., indicating their intent to offer securities to the public.)
- Rule 415
- A rule under the Securities Act of 1933 that allows companies to register securities for a delayed or continuous offering over a period of time. (iSpecimen Inc. is utilizing this rule, suggesting flexibility in how and when they will sell their securities to the public.)
- Non-accelerated filer
- A company that does not meet the filer requirements for accelerated or large accelerated filer status, typically due to lower public float or revenue. (Indicates iSpecimen Inc. is likely a smaller company with less public market presence.)
- Smaller reporting company
- A company that meets certain criteria for revenue and public float, allowing for scaled disclosure requirements. (Suggests iSpecimen Inc. has not yet reached a significant size in terms of market capitalization or revenue.)
- Emerging growth company
- A company that has total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year, and is eligible for scaled disclosure requirements. (Highlights that iSpecimen Inc. is in an early stage of development and may benefit from reduced regulatory and reporting burdens.)
Year-Over-Year Comparison
This filing is an amendment (S-1/A) to an initial registration statement (S-1). As such, it primarily updates the offering mechanics and regulatory disclosures rather than presenting year-over-year financial performance comparisons. The company's classification as a non-accelerated filer, smaller reporting company, and emerging growth company suggests it is in an early stage of its public market journey, with no prior public filing data to compare against in this specific amendment.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on May 23, 2025 by Robert Bradley Lim regarding iSpecimen Inc. (ISPC).